NCT04512846 Comparison of Efficacy in SBRT of Large HCC With or Without TACE
| NCT ID | NCT04512846 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing 302 Hospital |
| Condition | Large HCC Patients |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2020-08-01 |
| Primary Completion | 2023-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2020-08-01 with a primary completion date of 2023-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to compare efficacy and adverse reactions of large hepatocellular carcinoma participants (5-10cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The investigators will optimize the combined treatment schedule of SBRT for hepatocellular carcinoma participants by comparing overall survival rates, progression-free survival rates and local control and adverse reaction occurrence rates in the two groups.
Eligibility Criteria
Inclusion Criteria: * primary HCC diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of HCC or by pathology * single lesion and longest tumor diameter were 5-10cm; * CP-A or B classification; * Eastern Cooperative Oncology Group (ECOG) score 0-1; * distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are more than 5 mm * unsuitable for other therapies, such as patients with heart disease, uncontrolled diabetes, uncontrolled hypertension, etc. * rejecting other therapies such as resection, liver transplantation, etc. * platelet count≥50 × 109/L, white blood count≥1.5 × 109/L; * patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative. Exclusion Criteria: * tumor thrombus; * lymph node involvement; * extrahepatic metastasis.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04512846 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 80 Years, studying Large HCC Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04512846 currently recruiting?
Yes, NCT04512846 is actively recruiting participants. Contact the research team at 519299998@qq.com for enrollment information.
Where is the NCT04512846 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT04512846 clinical trial?
NCT04512846 is sponsored by Beijing 302 Hospital. The trial plans to enroll 100 participants.